Skip to content
My WebMD Sign In, Sign Up
ritonavir

Interactions

Selected 3A4 Inhibitors/Cisapride

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, your body may not process cisapride properly.

What might happen:

Your blood levels of cisapride may increase and cause life-threatening effects to your heart.

What you should do about this interaction:

Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. They may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

References:

1.Agenerase (amprenavir) Capsules US prescribing information. GlaxoSmithKline May, 2005.

2.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company August, 2013.

3.Reyataz (atazanavir sulfate) Australian product information. Bristol-Myers Squibb Pharmaceuticals January 8, 2004.

4.Prezista (darunavir) US prescribing information. Tibotec Inc. November, 2013.

5.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline February, 2013.

6.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. February, 2011.

7.Norvir (ritonavir) US prescribing information. Abbott Laboratories November, 2012.

8.Prepulsid (cisapride) US prescribing information. Janssen Pharmaceutica Products, L.P. January, 2000.

9.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories January, 2013.

10.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.

11.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. February, 2012.

12.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. May, 2013.

13.Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) prescribing information. Gilead Sciences, Inc. October, 2013.

14.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

More about Drugs and Medications

URAC: Accredited Health Web Site HONcode Seal AdChoices